Literature DB >> 24711465

Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue.

Aldrin Anthony Dung Dung1, Akhila Kumar Panda.   

Abstract

On the basis of evidence from clinical trials, contraindications to the use of interferon (INF) are pregnancy, epilepsy and depression. Management of multiple sclerosis during pregnancy is a difficult issue because of pregnancy-related complications and fear of congenital anomalies due to exposure to disease-modifying therapy. In different series, INF therapy was withdrawn before or after variable periods of exposure. This case illustrates a 26-year-old woman diagnosed with relapsing remitting multiple sclerosis who was treated with a weekly regimen of intramuscular INF-β 1a (Avonex). She had received this treatment throughout her pregnancy without any further exacerbations of symptoms or any untoward pregnancy-related complications. In contrast to different series, our patient had the longest exposure to INF-β during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24711465      PMCID: PMC3987290          DOI: 10.1136/bcr-2013-201273

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008.

Authors:  Stephanie J Ventura; Sally C Curtin; Joyce C Abma; Stanley K Henshaw
Journal:  Natl Vital Stat Rep       Date:  2012-06-20

2.  The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort.

Authors:  R Boskovic; R Wide; J Wolpin; D J Bauer; G Koren
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

Review 3.  Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.

Authors:  M Sandberg-Wollheim; D Frank; T M Goodwin; B Giesser; M Lopez-Bresnahan; M Stam-Moraga; P Chang; G S Francis
Journal:  Neurology       Date:  2005-08-10       Impact factor: 9.910

Review 4.  Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Authors:  Ellen Lu; Bing Wei Wang; Colleen Guimond; Anne Synnes; Dessa Sadovnick; Helen Tremlett
Journal:  Neurology       Date:  2012-08-29       Impact factor: 9.910

5.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.

Authors:  Sandra Vukusic; Michael Hutchinson; Martine Hours; Thibault Moreau; Patricia Cortinovis-Tourniaire; Patrice Adeleine; Christian Confavreux
Journal:  Brain       Date:  2004-05-06       Impact factor: 13.501

Review 9.  Multiple sclerosis and pregnancy: therapeutic considerations.

Authors:  Maria K Houtchens; Channa M Kolb
Journal:  J Neurol       Date:  2012-08-25       Impact factor: 4.849

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  5 in total

Review 1.  Management of women with multiple sclerosis through pregnancy and after childbirth.

Authors:  Patricia K Coyle
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

2.  Pregnancy in multiple sclerosis: a questionnaire study.

Authors:  Nadja Borisow; Friedemann Paul; Stephanie Ohlraun; Daniel Pach; Felix Fischer; Jan Dörr
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 3.  Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.

Authors:  Ramón Villaverde-González
Journal:  Degener Neurol Neuromuscul Dis       Date:  2022-01-05

Review 4.  Immunosuppressive drugs and fertility.

Authors:  Clara Leroy; Jean-Marc Rigot; Maryse Leroy; Christine Decanter; Kristell Le Mapihan; Anne-Sophie Parent; Anne-Claire Le Guillou; Ibrahim Yakoub-Agha; Sébastien Dharancy; Christian Noel; Marie-Christine Vantyghem
Journal:  Orphanet J Rare Dis       Date:  2015-10-21       Impact factor: 4.123

5.  Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience.

Authors:  Aurora Zanghì; Emanuele D'Amico; Graziella Callari; Clara Grazia Chisari; Giovanna Borriello; Luigi Maria Edoardo Grimaldi; Francesco Patti
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.